Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Sarcoma 27Breast Neoplasms 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Large B-Cell, Diffuse 19Ovarian Neoplasms 14Neoplasms 14Lymphoma 12Burkitt Lymphoma 11Neoplasm Metastasis 10Recurrence 9Lymphoma, Non-Hodgkin 9Triple Negative Breast Neoplasms 8Neuroblastoma 7Fallopian Tube Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell, Peripheral 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, Follicular 5Lymphoma, B-Cell 5Leukemia 5Hodgkin Disease 5Unspecified Adult Solid Tumor, Protocol Specific 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Multiple Myeloma 4Lymphoma, T-Cell 4Lung Neoplasms 4Liposarcoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Biphenotypic, Acute 4

Interventions

Everolimus 10lutetium Lu 177 dotatate 5Magnetic Resonance Spectroscopy 5pasireotide 4Specimen Handling 3Positron Emission Tomography Computed Tomography 3Fluorodeoxyglucose F18 3(177)Lu-DOTA-EB-TATE 3olaparib 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2FAPI-46 2veliparib 1vandetanib 1trifluridine tipiracil drug combination 1toripalimab 1tislelizumab 1talazoparib 1surufatinib 1romidepsin 1peposertib 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1fosbretabulin 1fludarabine phosphate 1exemestane 1decitabine and cedazuridine drug combination 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroendocrine Tumors × Doxorubicin × Clear all
NCT01970540 2020-03-09

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

PharmaMar

Phase 1 Completed
122 enrolled 19 charts
EndocrineNET

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡